GoodRx (GDRX) – Investment Analysts’ Recent Ratings Changes

GoodRx (NASDAQ: GDRX) recently received a number of ratings updates from brokerages and research firms:

• 8/13/2026 – GoodRx had its “neutral” rating reaffirmed by UBS Group AG. They now have a $3.75 price target on the stock.
• 8/11/2026 – GoodRx had its price target raised by TD Cowen from $4.00 to $5.00. They now have a “buy” rating on the stock.
• 8/11/2026 – GoodRx had its price target raised by Citigroup Inc. from $4.00 to $5.00. They now have a “buy” rating on the stock.
• 8/7/2026 – GoodRx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 8/7/2026 – GoodRx had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $4.00 price target on the stock.
• 8/7/2026 – GoodRx had its price target raised by Wells Fargo & Company from $3.50 to $5.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – GoodRx was given a new $5.00 price target by Leerink Partners.
• 7/23/2026 – GoodRx was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 7/23/2026 – GoodRx had its “buy” rating reaffirmed by Citigroup Inc..
• 7/8/2026 – GoodRx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.